218 related articles for article (PubMed ID: 26968400)
1. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections.
; Heddle NM; Boeckh M; Grossman B; Jacobson J; Kleinman S; Tobian AA; Webert K; Wong EC; Roback JD
Transfusion; 2016 Jun; 56(6 Pt 2):1581-7. PubMed ID: 26968400
[TBL] [Abstract][Full Text] [Related]
2. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
[TBL] [Abstract][Full Text] [Related]
3. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.
Mainou M; Alahdab F; Tobian AA; Asi N; Mohammed K; Murad MH; Grossman BJ
Transfusion; 2016 Jun; 56(6 Pt 2):1569-80. PubMed ID: 26826015
[TBL] [Abstract][Full Text] [Related]
4. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
[TBL] [Abstract][Full Text] [Related]
5. Survey of Institutional Policies for Provision of "CMV-Safe" Blood in Ontario.
Finlay L; Nippak P; Tiessen J; Isaac W; Callum J; Cserti-Gazdewich C
Am J Clin Pathol; 2016 Nov; 146(5):578-584. PubMed ID: 28430958
[TBL] [Abstract][Full Text] [Related]
6. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
7. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
Wu Y; Zou S; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Wang JH; Champion M; Fang C; Dodd R
Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585
[TBL] [Abstract][Full Text] [Related]
8. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients.
Narvios AB; de Lima M; Shah H; Lichtiger B
Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143
[TBL] [Abstract][Full Text] [Related]
9. Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions.
Josephson CD; Castillejo MI; Caliendo AM; Waller EK; Zimring J; Easley KA; Kutner M; Hillyer CD; Roback JD
Transfus Med Rev; 2011 Apr; 25(2):125-32. PubMed ID: 21345642
[TBL] [Abstract][Full Text] [Related]
10. Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy.
Delaney M; Mayock D; Knezevic A; Norby-Slycord C; Kleine E; Patel R; Easley K; Josephson C
Transfusion; 2016 Aug; 56(8):1945-50. PubMed ID: 27080192
[TBL] [Abstract][Full Text] [Related]
11. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
12. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
[TBL] [Abstract][Full Text] [Related]
13. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
[TBL] [Abstract][Full Text] [Related]
14. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
[TBL] [Abstract][Full Text] [Related]
15. Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation.
Shigemura T; Yanagisawa R; Komori K; Morita D; Kurata T; Tanaka M; Sakashita K; Nakazawa Y
Transfusion; 2019 Oct; 59(10):3065-3070. PubMed ID: 31322734
[TBL] [Abstract][Full Text] [Related]
16. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients.
Nash T; Hoffmann S; Butch S; Davenport R; Cooling L
Transfusion; 2012 Oct; 52(10):2270-2. PubMed ID: 23110735
[No Abstract] [Full Text] [Related]
17. Prevention of transfusion-transmitted cytomegalovirus infection.
Pamphilon DH; Rider JR; Barbara JA; Williamson LM
Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
[TBL] [Abstract][Full Text] [Related]
18. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
[TBL] [Abstract][Full Text] [Related]
19. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
20. Frozen deglycerolyzed blood prevents transfusion-acquired cytomegalovirus infections in neonates.
Taylor BJ; Jacobs RF; Baker RL; Moses EB; McSwain BE; Shulman G
Pediatr Infect Dis; 1986; 5(2):188-91. PubMed ID: 3005998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
